DRAFT
Briefing document for Member States and European Commission on Article 13.1 health claims list
Panel on Dietetic Products, Nutrition and Allergies

FOR COMMENTS
Deadline: 1 October 2009

Introduction
In July 2008 the European Commission requested EFSA to give a scientific opinion on the Community list of permitted health claims pursuant to Article 13.1 of Regulation 1924/2006 on nutrition and health claims made on foods. To this end EFSA received from the European Commission the terms of reference and a consolidated list of claims submitted by Member States containing over 4000 main entry health claims with corresponding conditions of use and references for about around 10,000 similar claims. The list is the result of a consolidation process carried out by the Commission after examining 44,000 claims supplied by Member States (documents are available on: http://www.efsa.europa.eu/panels/nda/claims/article13.htm).

The consolidated list has been screened by EFSA and for those health claims for which EFSA considered that sufficient information had been provided, EFSA started the assessment. In this context, the first series of opinions covering around 500 health claims was adopted by the NDA Panel on 2 July 2009.

Health claims (over 2000) for which EFSA considered that more information or clarification was needed have been sent back to the European Commission/ Member States for clarification. In addition, a number of claims were referred back to the Commission in June 2009 for consideration of their eligibility (about 130 product specific claims and comparative claims).

In the light of the experience gained, EFSA has prepared the present briefing document to update Member States and the European Commission on the evaluation of Article 13.1 health claims. The briefing document will be updated as appropriate as additional issues are addressed.

1 Art. 13 health claims, often referred to as general function claims, are health claims other than those referring to the reduction of disease risk and to children development and health. Article 13 claims describe or refer to the role of a nutrient or other substance in the functions of the body, or to the psychological and behavioural functions, or to slimming or weight control or to a reduction in the sense of hunger or to an increase in the sense of satiety or to the reduction of the available energy from the diet.
The following topics are addressed in this briefing document:

1. Overview of main issues addressed by the NDA Panel in evaluation of Art 13.1 claims
2. How does the NDA Panel decide whether a claim is substantiated?
3. What is the totality of the available scientific data?
4. What are pertinent studies for substantiation of a claim?
5. On what basis does EFSA propose wordings of claims?
6. To what extent should a food/constituent be characterised?
7. How should the claimed effect be shown to be beneficial?
8. Procedural aspects
9. Compliance eligibility issues for health claims on the Art. 13 list
10. Outstanding claims
1. **Overview of main issues addressed by the NDA Panel in evaluation of Art 13.1 claims**

The Terms of Reference (TOR) provided to EFSA for the Article 13(1) health claims list are consistent with the approach adopted by EFSA in evaluation of claims under Articles 13.5 and 14 of the Regulation. Thus, EFSA has adopted a similar approach to evaluation of Article 13(1) health claims, with some differences noted in appropriate sections following.

Each relationship between a food/constituent and a claimed effect is assessed separately; however, individual assessments are combined, as appropriate, to form coherent opinions.

In assessing each specific food/health relationship that forms the basis of a health claim the NDA Panel considers the extent to which:

- the food/constituent is defined and characterised;
- the claimed effect is defined and is a beneficial nutritional or physiological effect (“beneficial to human health”);
- a cause and effect relationship is established between the consumption of the food/constituent and the claimed effect (for the target group under the proposed conditions of use);

and, if a cause and effect relationship is considered to be established, whether:

- the quantity of food/pattern of consumption required to obtain the claimed effect can reasonably be consumed within a balanced diet;
- the proposed wording reflects the scientific evidence;
- the proposed wording complies with the criteria for the use of claims specified in the Regulation;
- the proposed conditions/restrictions of use are appropriate.

Because health claims are assessed on a case by case basis, the detailed application of these steps may vary.

Substantiation of the claim is dependent on a favourable outcome of the assessment of both (1) whether the food/constituent is sufficiently defined and characterised and (2) whether the claimed effect of the food/constituent in the identified function is sufficiently defined and is beneficial. Thus, a cause and effect relationship is considered not to be established if the outcome of either of these assessments is unfavourable.

2. **How does the NDA Panel decide whether a claim is substantiated?**

The TOR specify that EFSA should consider, and provide advice on whether the beneficial effect of the food on the function is substantiated by generally accepted scientific evidence by taking into account the totality of the available scientific data, and by weighing the evidence. In this context EFSA is invited to comment on the nature and quality of the totality of the evidence provided according to consistent criteria. In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent to which:

- a cause and effect relationship has been established between consumption of the
food and the claimed effect in humans and whether the magnitude of the effect is related to the quantity consumed;

- the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

In assessing each specific food/health relationship that forms the basis of a claim the NDA Panel makes a scientific judgement on the extent to which a cause and effect relationship is established between the consumption of the food/constituent and the claimed effect (for the target group under the proposed conditions of use). All the evidence from the pertinent studies (i.e., studies from which scientific conclusions can be drawn for substantiation of the claim) is weighed with respect to its overall strength, consistency and biological plausibility, taking into account the quality of individual studies and with particular regard to the population group for which the claim is intended and the conditions of use proposed for the claimed effect. A grade is not assigned to the evidence. While studies in animals or in vitro may provide supportive evidence, human data are central for the substantiation of the claim. This procedure is in agreement with the hierarchy of evidence as described in the EFSA guidance (document is available on: http://www.efsa.europa.eu/EFSA/efsaloCALE-1178620753812_1178623592448.htm).

Each relationship between a food/constituent and a claimed effect is assessed separately. There is no pre-established formula as to how many or what type of studies are needed to substantiate a claim. However, the NDA panel considers what the accepted norms are in the relevant research fields and EFSA consults experts from various disciplines, as appropriate.

The outcome of each assessment is one of three possible conclusions:

1. **A cause and effect relationship has been established between the consumption of the food/constituent and the claimed effect.**

   This represents the best judgement of the NDA panel on whether a cause and effect relationship is established between consumption of the food/constituent and the claimed effect by the evidence provided (i.e. that the claim is substantiated by ‘generally accepted scientific evidence’).

2. **The evidence provided is insufficient to establish a cause and effect relationship between the consumption of the food/constituent and the claimed effect.**

   This represents the best judgement of the NDA panel that although there is scientific evidence supporting a cause and effect relationship, the evidence is not conclusive (i.e. that the claim is not substantiated by ‘generally accepted scientific evidence’).

3. **A cause and effect relationship is not established between the consumption of the food/constituent and the claimed effect.**

   The NDA panel considers that there is, at most, limited scientific evidence supporting a cause and effect relationship and the claim is not substantiated by ‘generally accepted scientific evidence’.

3. **What is the totality of the available scientific data?**

   The totality of data refers to all studies available to EFSA that are considered pertinent (i.e. the studies from which scientific conclusions can be drawn for substantiation of the
claim), including those that support the relationship as well as studies showing no effect and/or opposing effects.

EFSA uses the references received from the Member States and references received directly from stakeholders. In the assessment the Panel may use data which are not included in the references provided if they are considered pertinent to the claim. However, EFSA is not required to search for additional references.

There are several limitations regarding the availability of documents cited in the references provided, including inaccurate or incomplete references, references to documents which are not readily accessible (e.g. published in journals not readily available), and references to documents in languages other than English.

EFSA carries out the evaluation of claims with the data available to it, taking into account the availability of the documents cited in the references provided. EFSA notes that it has no assurance that the references provided represent all data pertinent to the claim, i.e. that they include evidence of no effect and/or opposing effects as well as evidence that supports the relationship.

For claims for which there is well established concensus among scientific experts as to their substantiation, e.g. many of the functions of the essential nutrients, EFSA may rely on such concensus provided by reports from authoritative bodies.

4. What are pertinent studies for substantiation of a claim?

In considering whether the studies identified by the references provided are pertinent (i.e. studies from which scientific conclusions can be drawn for the substantiation of the claim), the NDA Panel addresses the following questions:

- Have the studies been carried out with the food/constituent for which the claim is made?
- Have the human studies used an appropriate outcome measure(s) of the claimed effect?
- How do the conditions under which the human studies were performed relate to the conditions of use (e.g. food/constituent quantity and pattern of consumption) proposed for the claim?
- Have the human studies been carried out in a study group representative of the population group for which the claim is intended? Can the results obtained in the studied population be extrapolated to the target population?
- To what extent can evidence derived from studies in animals/in vitro support the claimed effect in humans?

As human data are central for the substantiation of a claim, particular attention is given to whether the human studies provided are pertinent to the claim.

5. On what basis does EFSA propose wordings of claims?

In the TOR, EFSA is requested to consider the claimed effect on the function, and provide advice on the extent to which the wording used to express the claim reflects the scientific evidence and complies with the criteria laid down in the Regulation.
For claims for which a cause and effect relationship has been established, EFSA considers whether the proposed wording reflects the scientific evidence and complies with the criteria laid down in the Regulation (e.g. it should not refer only to general, non-specific health benefits of the food/constituent). If not, EFSA may propose an appropriate wording.

It should be noted that the wording adopted by the Commission during authorisation may need to take into account aspects other than agreement with the scientific evidence, e.g. understanding by consumers.

6. **To what extent should a food/constituent be characterised?**

The TOR specifies that EFSA should consider, and provide advice on, whether adequate information is provided on the characteristics of the food which may influence the specific physiological effect that is the basis of the claim.

Health claims can be made on a food category, a food or a food constituent (e.g. a nutrient, or other substance, or a combination of nutrients/other substances) and these are covered under the term “food/constituent”.

EFSA considers whether the specific food/constituent as provided in the consolidated list is sufficiently defined and characterised to establish that the studies provided for substantiation of the claim were performed with the food/constituent in respect of which the claim is made. Characterisation should be also sufficient to allow appropriate conditions of use to be defined. Although not required for substantiation of a claim, characterisation should also be sufficient to allow control authorities to verify that the food/constituent which bears a claim is the same one that was the subject of a community authorisation.

EFSA considers whether the information provided includes those characteristics considered pertinent to the claimed effect, i.e. those that may influence the specific physiological effect that is the basis of the claim.

It may be necessary to distinguish between a specific formulation, a specific constituent or combination of constituents. If the claim is for an individual constituent, then substantiation of the claim is based on studies performed with this constituent. However, if the claim is for a specific formulation or fixed combination of constituents, then studies are needed on this specific formulation or combination. In the latter case EFSA considers whether sufficient information is provided to identify the role of each constituent proposed to contribute to the claimed effect.

For a food category (e.g. ‘wholegrain’, ‘dairy’), EFSA considers whether the information provided sufficiently addresses the variability between individual foods for those characteristics considered pertinent to the claimed effect. For plant products, EFSA considers whether the information provided includes the scientific name, the part used and the preparation procedure. The panel also considers whether the food/constituent has been sufficiently characterised with respect to the claimed effect and the proposed conditions of use, taking into account information extracted from standard reference textbooks.

For microorganisms (e.g. bacteria, yeast), EFSA considers whether, in addition to species identification, sufficient information is provided for the characterisation (genetic typing) at strain level by internationally accepted molecular methods and naming of strains according to the International Code of Nomenclature. Although not required for
substantiation of a claim, it is also desirable that strains are deposited in an internationally recognized culture collection (with access number) for control purposes. In case of combination of more than one microorganism, the Panel considers that if one microorganism used in the combination is not sufficiently characterised, the combination proposed is not sufficiently characterised.

The characterisation of food constituents that are microorganisms is based on evaluation of available references up to end December 2008, including the following:

- The information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders;
- Generally available data obtained by searching Pubmed and Web of Science databases by using the strain name as search term.

Some foods/constituents are classified only on the basis of the claimed effect, i.e. the name of the food/constituent contains a description or indication of a beneficial effect on a function (e.g. non-cariogenic, low GI, antioxidants). Claims on such foods/constituents cannot be substantiated because these foods/constituents cannot be sufficiently characterised without substantiation of the claim.

7. How should the claimed effect be shown to be beneficial?

According to Regulation EC (No) 1924/2006, the use of nutrition and health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect.

In the TOR, EFSA is requested to consider the claimed effect on the function, and provide advice on the extent to which the claimed effect in the identified function is beneficial.

In assessing each claim, the NDA Panel makes a scientific judgement on whether the claimed effect is considered to be a beneficial nutritional or physiological effect in the context of the specific claim as described in the information provided. For function claims, a beneficial effect may relate to maintenance or improvement of a function.

EFSA considers whether the claimed effect as provided in the consolidated list is sufficiently defined to establish that the studies identified for substantiation of the claim were performed with an appropriate outcome measure(s) of that claimed effect. Thus, it may be necessary to distinguish between different possible effects or interpretations.

The Panel considers whether the claimed effect refers to a specific health claim (and are not general and non-specific) as required by Regulation (EC) No 1924/2006. The claimed effect needs to be specific enough to be testable and measurable by generally accepted methods. For example, “gut health” is too general (unclear what measure can be used) but ‘transit time’ is specific (measurable by generally accepted methods).

For claims for which the information on the list is unclear as to the definition of the claimed effect, EFSA will use its best judgement to identify the claimed effect, e.g. by reference to the proposed wordings as well as the health relationship. EFSA will also use its best judgement to identify the appropriate target group for the claim where this information is not provided.
8. Procedural aspects

EFSA has received from the European Commission nine Access databases with a consolidated list of 4,185 main health claim entries with around 10,000 similar health claims. The similar health claims were accompanied by the conditions of use and scientific references. Subsequently, EFSA combined the databases into one master database which has been published on the EFSA website in January 2009. Since the publication of the list, a number of changes have been made to the list (reallocating of similar health claims which had been accidentally placed under a wrong main health claim entry, adding missing similar claims) upon request of the Commission and Member States. An updated access database taking into account these changes will be published on the EFSA website this year.

The references to the scientific justifications provided by Member States were either included in the access database or were provided in separate files. In addition, full-text copies of references were provided directly to EFSA from stakeholders. The deadline for submission of these references was end of 2008. In some instances, references provided to EFSA were referring to papers which were submitted for publication. In case the publication had in the meanwhile taken place, EFSA has included the correct citation in the list of references and this may result in some references carrying a 2009 publication date.

For those claims for which EFSA considers that sufficient information has been provided for evaluation, a full list of the references to be used for evaluation, identifying the references associated with each health claim (main entry), has been published on the EFSA website in September 2009 (http://www.efsa.europa.eu/panels/nda/claims/article13.htm).

Some issues related to the references provided are covered in section 3.

In order to ensure consistency during the process and to keep the workload manageable, EFSA will publish claims opinions in series as they are adopted at specific plenary meetings of the NDA Panel. Assessments of individual claims will be combined, as appropriate, to form coherent opinions. The first series of claims opinions will be published on the EFSA website in September 2009.

EFSA’s contact point for any issues related to the Article 13 list is the European Commission/Member States.

9. Compliance/eligibility issues for health claims on the Art. 13 list

In the TOR, EFSA is requested to consider the claimed effect on the function, and provide advice on the extent to which the wording used to express the claimed effect complies with the criteria laid down in the Regulation.

Such criteria include:

- General, non-specific claims - reference to general, non-specific benefits of the nutrient or food for overall good health or health-related well-being may only be made if accompanied by a specific health claim included in the lists provided for in Article 13 or 14. (Article 10.3).

- Claims that encourage excess consumption of a food – the use of health claims
shall not encourage or condone excess consumption of a food (art 3c and Recital 18).

- The claimed effect must be beneficial - the use of health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial physiological effect (Article 5.1(a)).

- Claims on foods/constituents with no independent role in the claimed effect - the use of health claims shall only be permitted if the presence, absence or reduced content in a food or category of food of a nutrient or other substance, in respect of which the claim is made, has been shown to have a beneficial physiological effect (Article 5.1(a)). EFSA considers whether the food/constituent has an independent role in the claimed effect or whether its role is based on the inclusion or replacement (i.e., substitution) of other substances.

**Borderline issues**

In the Article 13 list, there are some claims that refer to the maintenance of a function but the scientific evidence is based on a reduction of a (well established) risk factor for disease (e.g. maintenance of normal blood cholesterol level, based on evidence of LDL cholesterol reduction). EFSA notes the Commission guidance on the implementation of regulation EC 1924/2006, of December 2007 (http://ec.europa.eu/food/food/labellingnutrition/claims/index_en.htm): ‘when the claim mentions a disease risk factor generally recognised by scientific evidence, it should be considered as an Article 14 claim only when a reduction of this risk factor is stated, suggested or implied’ and ‘when a claim refers to a risk factor of a disease, without stating, suggesting or implying its reduction it is considered an Article 13 claim’. EFSA has evaluated claims for the maintenance of normal blood cholesterol concentrations under Article 13 although the evidence for substantiation of the claimed effect is based on studies showing a reduction of blood cholesterol. This has also been done for claims related to the maintenance of normal blood pressure.

In accordance with the Commission guidance on the Implementation of Regulation EC 1924/2006, of December 2007, claims which EFSA considers would only be scientifically justified for children are considered as Article 14 and are not evaluated.

Comparative claims – the Article 13 list contains a number of claims based on effects of a food/constituent when used in substitution of another food/constituent, e.g. effects of monounsaturated fats when replacing saturated fats, claims on low-fermentable carbohydrates and dental health or ‘non-cariogenic’ (all compared to a reference carbohydrate), some claims on satiety (improved compared to a reference food). The Commission guidance addressed comparative nutrition claims but did not consider comparative health claims.

Some foods/constituents are classified only on the basis of the claimed effect, i.e. when the name of the food/constituent contains a description or indication of an effect on a function (e.g. non-cariogenic, low GI, antioxidants). Claims on such foods/constituents cannot be substantiated because these foods/constituents cannot be sufficiently characterised without substantiation of the claim.

EFSA has referred back to the Commission/Member States in June 2009 a number of claims for consideration of their eligibility (about 130 product specific claims and comparative claims).
10. Outstanding claims

EFSA awaits clarification on the status of outstanding claims including:

- approximately 2,000 claims sent to Member States via the Commission for clarification/further information;
- claims that have been referred back to the Commission in June 2009 for consideration of their eligibility (about 130 product specific claims and comparative claims);
- An addendum to the list (300-500 claims).